Brought to you by 
Kleo gets global rights to IP from Yale
27 Apr 2021
Executive Summary
Yale University licensed newly created Kleo Pharmaceuticals Inc. worldwide rights to intellectual property surrounding antibody recruiting molecules (ARMs) and synthetic antibody molecules (SyAMs).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kleo gets global rights to IP from Yale
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice